Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Declines By 54.0%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 6,400 shares, a decline of 54.0% from the January 31st total of 13,900 shares. Based on an average trading volume of 10,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a report on Friday, November 29th. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday, February 12th.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ:CLGN opened at $3.50 on Friday. The company’s 50-day moving average is $3.77 and its 200 day moving average is $4.21. The company has a market capitalization of $40.09 million, a P/E ratio of -2.27 and a beta of 0.86. CollPlant Biotechnologies has a fifty-two week low of $3.20 and a fifty-two week high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. As a group, research analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Villere ST Denis J & Co. LLC lifted its stake in CollPlant Biotechnologies by 24.4% in the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies during the 3rd quarter valued at $112,000. AMH Equity Ltd lifted its position in shares of CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of CollPlant Biotechnologies during the 4th quarter valued at $38,000. Finally, Wells Fargo & Company MN lifted its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after buying an additional 4,405 shares during the last quarter. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.